CoChat

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic endoplasmic reticulum (ER) stress, which is adaptively managed by the unfolded protein response. Inositol-requiring enzyme 1α (IRE1α) is activated to splice X-box binding protein 1 (XBP1) mRNA, thereby increasing XBP1s protein, which in turn regulates genes responsible for protein folding and degradation during the unfolded protein response. In this study, we examined whether IRE1α-XBP1 pathway is a potential therapeutic target in MM using a small-molecule IRE1α endoribonuclease domain inhibitor MKC-3946. MKC-3946 triggered modest growth inhibition in MM cell lines, without toxicity in normal mononuclear cells. Importantly, it significantly enhanced cytotoxicity induced by bortezomib or 17-AAG, even in the presence of bone marrow stromal cells or exogenous IL-6. Both bortezomib and 17-AAG induced ER stress, evidenced by induction of XBP1s, which was blocked by MKC-3946. Apoptosis induced by these agents was enhanced by MKC-3946, associated with increased CHOP. Finally, MKC-3946 inhibited XBP1 splicing in a model of ER stress in vivo, associated with significant growth inhibition of MM cells. Taken together, our results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2011-07-366633

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 438

Metadata

Authors
Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., Kiziltepe, T., Ikeda, H., Kawano, Y., French, M., Blumenthal, M., Tam, V., Kertesz, N. L., Malyankar, U. M., Hokenson, M., Pham, T., Zeng, Q., Patterson, J. B., Richardson, P. G., Munshi, N. C., & Anderson, K. C.
Affiliations
  • Harvard University (US)
  • Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
  • MannKind Corporation (United States) (US)
Venue
Blood
Published
2012-06-14
Volume
119
Issue
24
Pages
5772-5781
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1993401552
Cited by
432
References
46
Citations by year
2026: 13 · 2025: 26 · 2024: 21 · 2023: 22 · 2022: 36 · 2021: 29 · 2020: 49 · 2019: 46 · 2018: 29 · 2017: 32 · 2016: 32 · 2015: 31 · 2014: 36 · 2013: 24 · 2012: 5
FWCI
14.69
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p01ca078378-15)
  • U.S. Public Health Service (SPOREP50100707)
  • National Cancer Institute (P01-CA078378, P50CA100707, R01CA050947)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
multiple myeloma, IRE1α, XBP1 splicing, endoplasmic reticulum stress, unfolded protein response, bortezomib, 17-AAG, CHOP, apoptosis, mesenchymal stem cells, interleukin-6, small molecule inhibitors
MeSH terms
Bortezomib, Regulatory Factor X Transcription Factors, X-Box Binding Protein 1, Animals, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Cells, Boronic Acids, DNA-Binding Proteins, Endoribonucleases, Enzyme Activation, Enzyme Inhibitors, Humans, Multiple Myeloma, Pyrazines, RNA Splicing, RNA, Messenger, Transcription Factors, Signal Transduction, Interleukin-6, Benzoquinones, Cell Death, Stromal Cells, Protein Serine-Threonine Kinases, eIF-2 Kinase, Cell Line, Tumor, Lactams, Macrocyclic, Cell Proliferation, Mice, Unfolded Protein Response, Endoplasmic Reticulum Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2011-07-366633
The paper
Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., Kiziltepe, T., Ikeda, H., Kawano, Y., French, M., Blumenthal, M., Tam, V., Kertesz, N. L., Malyankar, U. M., Hokenson, M., . . . Anderson, K. C. (2012). Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. https://doi.org/10.1182/blood-2011-07-366633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.